归楼通络方治疗慢阻肺合并肺高血压的前瞻性多中心随机对照试验
本研究纳入104例慢阻肺合并肺高血压患者,随机分为常规治疗组与联用归楼通络方组,评估疗效与安全性并探索机制。结果显示归楼通络方可改善中医证候积分、肺动脉收缩压、肺功能、动脉血气、BNP、D-二聚体、6分钟步行距离及CAT、mMRC、WHO-FC评分,并调节肠道菌群与代谢。
要点
- 归楼通络方联用常规治疗可改善慢阻肺合并肺高血压患者的多项临床指标。
- 归楼通络方可能通过调节肠道菌群和代谢途径发挥治疗作用。
- 研究为前瞻性多中心随机对照试验,但样本量有限,需进一步验证。
核心结论
- 归楼通络方可有效治疗慢阻肺合并肺高血压患者,提高临床疗效,并调节代谢状态和肠道菌群组成。
研究设计与样本
- 前瞻性多中心随机对照试验,共纳入104例慢阻肺合并肺高血压患者,随机分为常规治疗组和联用归楼通络方组。
主要发现
- 两组治疗后中医证候积分均显著降低(P < 0.001)。
- 归楼通络方组肺动脉收缩压、FEV1、FEV1/FVC显著改善(P < 0.05),且治疗后优于对照组(P < 0.05)。
- 归楼通络方干预后PaO2、PaCO2、BNP、D-二聚体改善(P < 0.05)。
- 两组6分钟步行距离均增加(P < 0.001),归楼通络方组更优(P = 0.006)。
- 两组CAT评分、mMRC分级、WHO-FC均改善(P < 0.05),归楼通络方组更优(P < 0.05)。
关键数值与推荐
- 中医证候积分:两组治疗后均显著降低(P < 0.001)。
- 肺动脉收缩压、FEV1、FEV1/FVC:归楼通络方组显著改善(P < 0.05),且优于对照组(P < 0.05)。
- PaO2、PaCO2、BNP、D-二聚体:归楼通络方干预后改善(P < 0.05)。
- 6分钟步行距离:两组均增加(P < 0.001),归楼通络方组更优(P = 0.006)。
- CAT评分、mMRC分级、WHO-FC:两组均改善(P < 0.05),归楼通络方组更优(P < 0.05)。
临床怎么用
- 在常规治疗基础上联用归楼通络方可能改善慢阻肺合并肺高血压患者的中医证候、肺动脉压力、肺功能、血气指标、运动耐量和生活质量。
- 归楼通络方可能通过调节肠道菌群和代谢途径发挥作用,但需进一步研究确认。
局限性
- 样本量有限(104例),需更大规模试验验证。
- 机制探索基于肠道菌群和代谢组学,因果关系尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary hypertension (PH) is a serious and common complication in patients with chronic obstructive pulmonary disease (COPD), and this clinical gap has been newly emphasized in the GOLD 2025 guidelines. Guilou Tongluo Formula (GLTLF) is a traditional Chinese herbal prescription widely used in clinical practice for the treatment of COPD combined with PH (COPD-PH). However, there is a lack of high-quality clinical trials to support its efficacy, and the underlying mechanisms of action remain unclear. AIM OF THE STUDY: This study aims to evaluate the efficacy and safety of GLTLF in the treatment of COPD-PH, and to explore the potential mechanisms underlying its therapeutic effects. MATERIALS AND METHOD: A total of 104 patients with COPD-PH were randomized to receive either conventional therapy alone (Control group) or in combination with GLTLF (GLTLF group). Clinical efficacy was assessed by changes in traditional Chinese medicine (TCM) syndrome scores, pulmonary artery systolic pressure (PASP), pulmonary function, arterial blood gases, COPD Assessment Test (CAT), modified Medical Research Council (mMRC) grade, WHO functional class (WHO-FC), 6-min walk distance (6MWD), and laboratory parameters. Potential mechanisms were explored via gut metagenomic and metabolomic analyses. RESULTS: Clinical efficacy evaluation indicated that the TCM syndrome scores were significantly reduced in both groups post-treatment (P < 0.001). PASP, FEV1, and FEV1/FVC improved significantly in the GLTLF group (P < 0.05), and were superior to the control group post-treatment (P < 0.05). PaO2, PaCO2, BNP, and D-dimer improved after GLTLF intervention (P < 0.05). Both groups had increased 6MWD (P < 0.001), with the GLTLF group performing better (P = 0.006). CAT score, mMRC grade, and WHO-FC improved in both groups (P < 0.05), with superior outcomes in the GLTLF group (P < 0.05). Metagenomic sequencing revealed that GLTLF altered the structure and function of the gut microbiota in patients with COPD-PH. Metabolomic analysis identified a total of 87 differential metabolites following GLTLF intervention, which were significantly enriched in 18 metabolic pathways. CONCLUSION: GLTLF can effectively treat patients with COPD-PH, enhance clinical efficacy, and modulate both metabolic status and gut microbiota composition.
引用
- Liu K, Peng W, Yang X, et al. Efficacy and multi-omics regulatory effects of Guilou Tongluo formula in patients with chronic obstructive pulmonary disease combined with pulmonary hypertension: A prospective, multicenter, randomized controlled trial. J Ethnopharmacol. 2026. PMID: 41534755. doi:10.1016/j.jep.2026.121204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。